B
Bull
Bull · 25%AKYA
$1.21
シナリオ価格
$1.290
-0.066 (-5.15%)終値時点
Loading chart…
- High
- 1.640
- Open
- 1.410
- VWAP
- 1.41
- Vol
- 715.25K
- Mkt Cap
- 120.50M
- Low
- 1.290
- Amount
- 1.01M
- EV/EBITDA, TTM
- -7.63
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. It offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays.
バリュエーション指標
The current forward P/E ratio for Akoya Biosciences Inc (AKYA) is -2.50, compared to its 5-year average forward P/E of -5.67.
Alphio AI Price Scenarios for AKYA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
イベントタイムライン
ニュース
8.505-23NewsfilterKent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal
9.005-23PRnewswireNew Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs
8.505-21SeekingAlphaAkoya surges as unsolicited buyout offer risks Quanterix merger
7.004-28Globenewswire$HAREHOLDER ALERT: The M&A Class Action Firm Urges Stockholders of AKYA, WTMA, PLYA, QTRX to Act Now
7.004-24GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PPBI, SSBK, AKYA on Behalf of Shareholders
AKYA FAQ — answered by Alphio AI
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. It offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。